research Switching Between Tofacitinib and Baricitinib in Alopecia Areata: A Review of Clinical Response
Switching between the medications tofacitinib and baricitinib can be effective for treating hair loss in alopecia areata.
Search
for
Sort by
Research
600-630 / 1000+ results 
research Baricitinib Safety for Events of Special Interest in Populations at Risk: Analysis from Randomised Trial Data Across Rheumatologic and Dermatologic Indications
Baricitinib, a drug for rheumatoid arthritis, atopic dermatitis, and alopecia areata, is generally safe with low risk of major side effects, even in patients with risk factors. It's also effective in promoting hair regrowth in alopecia areata patients.
research Ritlecitinib And Brepocitinib Demonstrate Significant Improvement In Scalp Alopecia Areata Biomarkers
Two drugs, ritlecitinib and brepocitinib, improved scalp hair loss condition markers.
research Topical Tofacitinib for Patients with Lichen Planopilaris and/or Frontal Fibrosing Alopecia
Topical tofacitinib cream may help treat certain hair loss conditions with fewer risks.
research Clinical Response to Adjunctive Platelet-Rich Plasma Injections in a Patient with Alopecia Universalis on Oral Tofacitinib
A woman with severe hair loss saw significant hair regrowth after adding platelet-rich plasma injections to her treatment with tofacitinib.
research Treatment of Moderate-to-Severe Alopecia Areata in Adolescents With Baricitinib: A Retrospective Review of 29 Patients
Baricitinib helped most teenagers with severe hair loss regrow hair and had mild side effects.
research COVID-19 Vaccination Related Exacerbations of Hair Loss in Patients With Moderate-to-Severe Alopecia Areata on Systemic Therapy
COVID-19 vaccines may rarely worsen hair loss in people with severe alopecia, but the benefits of vaccination still outweigh this risk.
research Delayed Granulomatous Eruption of the Nose Associated with Ruxolitinib
Ruxolitinib can cause a delayed skin reaction on the nose.
research Selective Inhibition of JAK3 Signaling Is Sufficient to Reverse Alopecia Areata
Blocking JAK3 signaling can reverse hair loss from alopecia areata.
research JAK Inhibition in the Treatment of Alopecia Areata: A Promising New Dawn?
JAK inhibitors are a promising new treatment for hair loss and nail problems in alopecia areata.
research Maintenance, Withdrawal, and Re-Treatment with Ritlecitinib and Brepocitinib in Patients with Alopecia Areata in a Single-Blind Extension of a Phase 2a Randomized Clinical Trial
Continuous treatment with ritlecitinib and brepocitinib is needed to maintain hair regrowth in alopecia areata.
research Epigallocatechin-3 Gallate Inhibits STAT-1/JAK2/IRF-1/HLA-DR/HLA-B and Reduces CD8 NKG2D Lymphocytes in Alopecia Areata Patients
EGCG may help treat alopecia areata by blocking certain immune responses and reducing specific harmful immune cells.
research Incidence Rates of Infections, Malignancies, Thromboembolism, and Cardiovascular Events in an Alopecia Areata Cohort from a US Claims Database
People with Alopecia Areata have more herpes simplex infections but similar rates of cancer, blood clots, and heart disease compared to those without it.
research Spontaneous Complete Resolution of Alopecia Totalis Post SARS-CoV-2 Infection
A woman's complete hair loss condition improved after recovering from COVID-19.
research Characteristics and Outcomes of Patients on Tofacitinib for Alopecia Areata or Rheumatoid Arthritis: A Retrospective Cohort Study
Patients with rheumatoid arthritis using tofacitinib had more serious side effects than those with alopecia areata.
research Effectiveness of OR-101, a Next Generation Highly Selective JAK3 Inhibitor, in a Humanized Murine Model of Alopecia Areata
OR-101 shows promise for treating alopecia areata by improving hair growth.
research Comparison of Ruxolitinib and a Collagen-Targeted PTH-Based Hair Cycle Stimulant on Hair Follicle Counts and Hair Growth in the C3H/HeJ Engrafted Mouse Model of Alopecia Areata
A PTH-based treatment improved hair regrowth better than ruxolitinib in a mouse model of hair loss.
research A Case of Topical Ruxolitinib Treatment Failure in Alopecia Areata
Topical ruxolitinib failed to regrow hair in a 66-year-old with alopecia areata.
research Efficacy of JAK 1/2 Inhibition in the Treatment of Diffuse Non-Scarring Alopecia Due to Systemic Lupus Erythematosus
Baricitinib might help treat hair loss in lupus patients, but more research is needed.
research Recovery of Nail Dystrophy: Potential New Therapeutic Indication of Tofacitinib
Tofacitinib may help treat nail dystrophy, especially when other treatments fail.
research Oral Tofacitinib and Systemic Corticosteroids, Alone or in Combination, in Patients With Moderate-to-Severe Alopecia Areata: A Retrospective Study
Both individual and combined treatments of tofacitinib and corticosteroids can help regrow hair in moderate-to-severe alopecia areata, but ongoing treatment may be necessary.
research Genes and Immune Response in Alopecia Areata: Review of the Alopecia Areata Research Summit First Day Proceedings
Alopecia areata involves complex immune and genetic factors, with potential treatment targets identified, but more research is needed.
research Baricitinib in Pediatric Chronic Immune Thrombocytopenia and Associated Autoimmune Conditions: A Case Report
Baricitinib improved platelet counts and alopecia in a 16-year-old with chronic immune thrombocytopenia.
research Baricitinib (Olumiant) for Severe Alopecia Areata Treatment Recommendations
Olumiant should be covered for severe alopecia areata if certain conditions are met.
research Efficacy of Baricitinib Compared to Conventional Therapy for Alopecia Areata
Baricitinib is effective for Alopecia Areata but requires careful patient history evaluation.
research Nanostructured Lipid Carriers Promote Percutaneous Absorption and Hair Follicle Targeting of Tofacitinib for Treating Alopecia Areata
Nanostructured lipid carriers effectively deliver tofacitinib to hair follicles, reversing hair loss in alopecia areata.
research The Roles of Exosomes in Regulating Hair Follicle Growth
Exosomes can help promote hair growth and may treat hair loss.
research Baricitinib as a Treatment for Myasthenia Gravis: A Case Report
Baricitinib successfully treated myasthenia gravis and alopecia in a patient.
research Current Best Evidence in Pigmentary Dermatology
Several treatments are effective for pigmentary disorders like vitiligo and melasma.
research Long-Term Efficacy and Safety of Baricitinib in Patients With Severe Alopecia Areata: 104-Week Results From BRAVE-AA1 and BRAVE-AA2
Baricitinib is effective and safe for long-term use in severe alopecia areata, improving hair regrowth and quality of life with few side effects.